• Report Adverse Event or Product Quality Complaint
  • US Site
  • Global Site
AstraZeneca Medical Information
  • Therapy Areas
    • All Therapeutic Areas
    • Cardiovascular
    • Immunology
    • Infection
    • Metabolic
    • Oncology
    • Renal
    • Respiratory
    • Rare Disease (Alexion)
  • Medications
  • Resources
    • Congress Library
    • Disease Education
    • Pipeline
    • Clinical Trials
    • Open innovation
    • Access 360
    • Affordability Programs
    • Sample Closet
    • Medical Education Grant
    • Rare Disease (Alexion)
  • Connect
    • Find an MSL
    • Request an MSL
    • Submit an MIR
    • Give Feedback
User
  • Login to My AZmedical
  • Register for My AZmedical

Search Medical Information

American Society of Nephrology (ASN) - Kidney Week 2025

November 5 - 9, 2025

  1. Chronic Kidney Disease
  2. FARXIGA (dapagliflozin)
  3. Hypertension
  4. Heart Failure/Chronic Kidney Disease
  5. LOKELMA (Sodium zirconium cyclosilicate)

html

Association between erythrocyte indices and roxadustat response in chronic kidney disease patients with anemia: ROXSTAR registry secondary analysis

html

Evaluating the economic impact of CKD patients on Germany's healthcare system: A 2023 claims data analysis

html

Exploring gender differences: CKD prevalence, diagnosis and treatment in hypertensive German patients – Insights from the InspeCKD study

pdf

Harnessing AI and Clinical Guidelines to Identify At-Risk CKD Patients and Optimize Management of CKD in the US

html

Innovative visualization of treatment effects in kidney disease trials using hierarchical composite endpoints

pdf

Risk of CKD progression in a real-world population eligible for the ZENITH-High Proteinuria trial

html

Roxadustat response by inflammation/iron status subgroups in peritoneal dialysis patients with renal anemia: A secondary analysis of the NANLING study

pdf

Association of Circulating Protein Levels with Kidney Outcome and Effects of Dapagliflozin: Proteomics analysis from DAPA-CKD

html

Cardio-kidney effects of dapagliflozin in patients at elevated cardiovascular risk with or without type 2 diabetes

html

Efficacy, mechanisms and safety of SGLT2 inhibitors in kidney transplant recipients

html

Sex differences in SGLT2i use complicating a treatment optimization program in a large network of nephrology practices

pdf

BP and urine albumin-to-creatinine ratio lowering by baxdrostat in participants in the FigHTN trial

pdf

Burden of Proteinuria in Patients with Chronic Kidney Diseases: Insights from the iCaReMe Global Registry

pdf

Kidney outcomes and mortality in patients with comorbid chronic kidney disease and heart failure (the CaRe study)

pdf

Effects of sodium zirconium cyclosilicate on volume status in hemodialysis: post hoc analysis from the DIALIZE-Outcomes trial

html

Management of hyperkalemia: Real-world insights from US patients and healthcare professionals in the TRACK study

pdf

Treatment Strategies in De Novo vs Recurrent Hyperkalemia: TRACK Study Insights

Disclaimer

Some content may have changed since publication. Some links may require registration/login to access the content. Any attached publications and/or any tables or figures derived from the publications are copyright-protected works. AstraZeneca has obtained permission from the copyright owner to use this work on this site. You may not reproduce, prepare derivative works from, display or distribute this work unless you obtain the permission of the copyright owner, or as otherwise might be permitted by law.

Request a field medical follow-up

Welcome to AstraZeneca
Medical Information

The information provided on this site is intended for use by healthcare professionals practicing in the US. The dissemination of this information may be subject to different medical and regulatory requirements in other countries.

This web site is intended to help healthcare professionals practicing in the US and AstraZeneca authorized persons find scientifically balanced, evidence-based information about AstraZeneca drugs, submit a question, ask for field medical follow-up, and explore links to professional and patient support resources.

Are you a healthcare professional practicing in the United States?

I am an AstraZeneca authorized person   What is an AstraZeneca authorized person?This website is only intended for healthcare professionals practicing in the United States and authorized AstraZeneca personnel. AstraZeneca US Headquarters personnel and US Field Medical personnel are authorized to browse and search the database for their own background knowledge and insight. US Field Sales personnel should not access or browse this site. None of the content of this site should be directly linked or distributed without approval.
I am not a healthcare professional practicing in the United States (Take me to AstraZeneca.com)
AstraZeneca Logo
Pharma Logo

This site is intended for healthcare professionals practicing in the US.

©2025 AstraZeneca. All rights reserved.

US-69609; US-91816; US-103094; US-106788

Last Updated 11/25

Contact Us

About Us

AstraZeneca-US.com

Grant Opportunities

Survey Feedback

Your Privacy Choices

Consumer Health Data Privacy Notice

Privacy Notice

Legal Notice

Cookie Preferences

US Site

Global Site

Report Adverse Event or Product Quality Complaint

Survey Feedback

Your Privacy Choices

Consumer Health Data Privacy Notice

Pharma Logo

Privacy NoticeLegal NoticeCookie Preferences